Skip to content

dr. Schelfhout Vanessa

Nucleaire Geneeskunde
contactgegevens
Geen artikels gevonden...
04/11/2022
Nucleaire Geneeskunde

Impact of 18F-PSMA-11 PET/CT on Management of Biochemical Recurrence and High-Risk Prostate Cancer Staging : 18F-PSMA-11 PET/CT and Impact on Prostate Cancer Management

https://pubmed.ncbi.nlm.nih.gov/35411446/dr. Schelfhout Vanessa
06/12/2023
Nucleaire Geneeskunde

High-Resolution 18F-FDG PET/CT for Assessing Three-Dimensional Intraoperative Margins Status in Malignancies of the Head and Neck, a Proof-of-Concept.

PMID: 34442033 PMCID: PMC8397229 DOI: 10.3390/jcm10163737dr. Schelfhout Vanessa
06/12/2023
Nucleaire Geneeskunde

[18F]FDG Uptake and Expression of Immunohistochemical Markers Related to Glycolysis, Hypoxia, and Proliferation in Indeterminate Thyroid Nodules.

PMID: 36253663 PMCID: PMC10172288 DOI: 10.1007/s11307-022-01776-4dr. Schelfhout Vanessa
11/01/2022
Nucleaire Geneeskunde

18F-PSMA-11 Versus 68Ga-PSMA-11 Positron Emission Tomography/Computed Tomography for Staging and Biochemical Recurrence of Prostate Cancer: A Prospective Double-blind Randomised Cross-over Trial.

PMID: 35690515 DOI: 10.1016/j.eururo.2022.05.010dr. Schelfhout Vanessa
10/01/2022
Nucleaire Geneeskunde

Impact of 18F-PSMA-11 PET/CT on Management of Biochemical Recurrence and High-Risk Prostate Cancer Staging : 18F-PSMA-11 PET/CT and Impact on Prostate Cancer Management.

PMID: 35411446 DOI: 10.1007/s11307-022-01724-2dr. Schelfhout Vanessa
Nucleaire Geneeskunde

“ The Invisible doctor”.

2022-12-12dr. Schelfhout Vanessa